Lexaria Bioscience Corp. (LEXX)
4.44
+0.26
(+6.22%)
USD |
NASDAQ |
Nov 13, 16:00
4.43
-0.01
(-0.23%)
After-Hours: 19:59
Lexaria Bioscience Enterprise Value : 3.413M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 3.413M |
| November 12, 2026 | 2.983M |
| November 11, 2026 | 3.743M |
| November 10, 2026 | 3.809M |
| November 09, 2026 | 3.578M |
| November 06, 2026 | 3.512M |
| November 05, 2026 | 2.966M |
| November 04, 2026 | 2.801M |
| November 03, 2026 | 2.735M |
| November 02, 2026 | 2.091M |
| October 30, 2026 | 1.843M |
| October 29, 2026 | 2.306M |
| October 28, 2026 | 1.529M |
| October 27, 2026 | 1.397M |
| October 26, 2026 | 0.9009M |
| October 23, 2026 | 1.165M |
| October 22, 2026 | 1.017M |
| October 21, 2026 | 0.7357M |
| October 20, 2026 | 0.4547M |
| October 19, 2026 | 0.3721M |
| October 16, 2026 | 0.8017M |
| October 15, 2026 | 1.017M |
| October 14, 2026 | 0.7357M |
| October 13, 2026 | 0.7026M |
| October 12, 2026 | 1.479M |
| Date | Value |
|---|---|
| October 09, 2026 | 1.562M |
| October 08, 2026 | 1.364M |
| October 07, 2026 | 1.793M |
| October 06, 2026 | 1.430M |
| October 05, 2026 | 0.653M |
| October 02, 2026 | 0.8348M |
| October 01, 2026 | 1.182M |
| September 30, 2026 | 1.281M |
| September 29, 2026 | 1.248M |
| September 28, 2026 | 1.405M |
| September 25, 2026 | 1.496M |
| September 24, 2026 | 1.644M |
| September 23, 2026 | 1.421M |
| September 22, 2026 | 1.397M |
| September 21, 2026 | 1.735M |
| September 18, 2026 | 1.430M |
| September 17, 2026 | 1.512M |
| September 16, 2026 | 1.190M |
| September 15, 2026 | 1.380M |
| September 14, 2026 | 1.942M |
| September 11, 2026 | 2.636M |
| September 10, 2026 | 2.768M |
| September 09, 2026 | 6.982M |
| September 08, 2026 | 11.56M |
| September 04, 2026 | 19.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Target Group, Inc. (Canada) | 11.72M |
| XORTX Therapeutics, Inc. | 1.774M |
| NervGen Pharma Corp. | 138.88M |
| Milestone Pharmaceuticals, Inc. | 63.15M |
| Appili Therapeutics, Inc. | 9.586M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.993M |
| Total Expenses (Quarterly) | 1.991M |
| EPS Diluted (Quarterly) | -1.204 |
| Earnings Yield | -118.9% |
| Normalized Earnings Yield | -115.96 |